Erschienen in:
01.06.2013 | Original Article
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide
verfasst von:
Luis Sanchez-Perez, Bryan D. Choi, Elizabeth A. Reap, Elias J. Sayour, Pamela Norberg, Robert J. Schmittling, Gerald E. Archer, James E. Herndon 2nd, Duane A. Mitchell, Amy B. Heimberger, Darell D. Bigner, John H. Sampson
Erschienen in:
Cancer Immunology, Immunotherapy
|
Ausgabe 6/2013
Einloggen, um Zugang zu erhalten
Abstract
B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral responses following vaccination has not been evaluated. We evaluated BLyS serum levels and antigen-specific antibody titers in 8 patients undergoing therapeutic temozolomide (TMZ)-induced lymphopenia, with concomitant vaccine against a tumor-specific mutation in the epidermal growth factor receptor (EGFRvIII). Our studies demonstrate that TMZ-induced lymphopenia corresponded with spikes in serum BLyS that directly preceded the induction of anti-EGFRvIII antigen-specific antibody titers, in some cases as high as 1:2,000,000. Our data are the first clinical observation of BLyS serum elevation and greatly enhanced humoral immune responses as a consequence of chemotherapy-induced lymphopenia. These observations should be considered for the development of future vaccination strategies in the setting of malignancy.